Teva Pharmaceutical and Medincell announced that the European Medicines Agency has accepted their Marketing Authorization Application for TEV-749, a long-acting injectable olanzapine for schizophrenia.
The subcutaneous formulation is administered every four weeks. The submission is backed by Phase 3 SOLARIS study results.
Teva’s Chief Medical Officer, Eric Hughes, stated: "TEV-749 has the potential to provide stability with the proven efficacy of olanzapine as a once-every-four-weeks treatment."
